The formation of Gain’s new Clinical Advisory Board marks a significant strategic step forward for Gain, as GT-02287 advances into Parkinson’s disease patients,” stated Gene Mack, CEO of Gain ...
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today ...